Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;18(12):1213-1220.
doi: 10.1007/s12094-016-1574-1.

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)

Affiliations

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)

A López-Pousa et al. Clin Transl Oncol. 2016 Dec.

Abstract

Soft-tissue sarcomas are uncommon and heterogeneous tumors of mesenchymal origin. A soft-tissue mass that is increasing in size, greater than 5 cm, or located under deep fascia are criteria for suspicion of sarcoma. Diagnosis, treatment, and management should preferably be performed by a multidisciplinary team in reference centers. MRI and lung CT scan are mandatory for local and distant assessment. A biopsy indicating histological type and grade is needed previous to the treatment. Wide surgical resection with tumor-free tissue margin is the primary treatment for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not likely of being improved with reexcision. Neoadjuvant and adjuvant chemotherapy improve survival in selected cases, usually in high-grade sarcomas of the extremities. In the case of metastatic disease, patients with exclusive lung metastasis could be considered for surgery. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. New drugs have shown activity in second-line therapy and in specific histological subtypes.

Keywords: Clinical guidelines; Sarcoma; Soft-tissue tumors; Uncommon tumors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest relating to the publication of this manuscript and compliance with ethical standards.

Figures

Fig. 1
Fig. 1
Primary management of STS algorithm

References

    1. Bhangu AA, Beard JA, Grimer RJ. Should soft tissue sarcomas be treated at a specialist centre? Sarcoma. 2004;8:1–63. doi: 10.1080/13577140410001679185. - DOI - PMC - PubMed
    1. Trieu J, Sinnathamby M, Di Bella C, Pianta M, Perera W, Slavin JL, et al. Biopsy and the diagnostic evaluation of musculoskeletal tumours: critical but often missed in the 21st century. ANZ J Surg. 2016;86(3):133–138. doi: 10.1111/ans.13251. - DOI - PubMed
    1. Noujaim J, Thway K, Sheri A, Keller C, Jones RL. Histology-driven therapy: the importance of diagnostic accuracy in guiding systemic therapy of soft tissue tumors. Int J Surg Pathol. 2016;24(1):5–15. doi: 10.1177/1066896915606971. - DOI - PubMed
    1. del Muro Garcia. X, Martin J, Lianes P, Cubedo Rl. SEOM clinical guidelines for the management of adult soft tissue sarcomas. Clin Transl Oncol. 2012;14:541–544. doi: 10.1007/s12094-012-0838-7. - DOI - PubMed
    1. O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–2241. doi: 10.1016/S0140-6736(02)09292-9. - DOI - PubMed